• 1. An easier analysis of complex mixtures with highly resolved and sensitivity enhanced 2D quantitative NMR: application to tracking sugar phosphates in plants?
  Soumaya Khlifi,Gregory Mouille,Jonathan Farjon Anal. Methods, 2017,9, 2328-2333
• 2. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 3. Aggregation kinetics and gel formation in modestly concentrated suspensions of oppositely charged model ceramic colloids: a numerical study
  M. A. Piechowiak,A. Videcoq,R. Ferrando,D. Bochicchio,C. Pagnoux,F. Rossignol Phys. Chem. Chem. Phys., 2012,14, 1431-1439
• 4. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 5. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls N-acyl amines
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty amides N-acyl amines
• Pharmaceutical and Biochemical Products Pharmaceutical Intermediates

Introduction to (2R,3R)-N,N,N’,N’-Tetramethyltartramide (CAS No. 26549-65-5)

(2R,3R-N,N,N’,N’-Tetramethyltartramide) is a chiral auxiliary and a key intermediate in the synthesis of various pharmaceutical compounds. With the CAS number 26549-65-5, this compound has garnered significant attention in the field of medicinal chemistry due to its unique structural properties and versatile applications. This article provides a comprehensive overview of its chemical characteristics, synthetic pathways, and recent advancements in its application within the pharmaceutical industry.

The compound (2R,3R)-N,N,N’,N’-Tetramethyltartramide belongs to the class of tartramide derivatives, which are known for their broad spectrum of biological activities. The presence of four methyl groups at the nitrogen atoms enhances its stability and reactivity, making it an invaluable building block in organic synthesis. Its chiral center at the carbon atoms C-2 and C-3 contributes to its role as a crucial chiral auxiliary in asymmetric synthesis.

In recent years, there has been a surge in research focusing on the development of enantioselective catalysts and chiral auxiliaries for the synthesis of optically active pharmaceuticals. (2R,3R)-N,N,N’,N’-Tetramethyltartramide has emerged as a preferred choice due to its high enantiomeric purity and excellent yields in catalytic reactions. Its ability to facilitate enantioselective transformations has been leveraged in the synthesis of complex drug molecules, particularly in the development of protease inhibitors and other bioactive compounds.

The synthetic route to (2R,3R)-N,N,N’,N’-Tetramethyltartramide involves a series of well-established chemical reactions that highlight its versatility. Typically, it is synthesized through the reaction of methyl tartrate with dimethylamine under controlled conditions. The stereochemistry is carefully controlled to ensure the formation of the (2R,3R) configuration. This process underscores the importance of precise reaction conditions and catalyst selection in achieving high enantiomeric excess.

One of the most notable applications of (2R,3R)-N,N,N’,N’-Tetramethyltartramide is in the synthesis of antiviral and anticancer agents. Its chiral framework provides a scaffold for designing molecules that interact selectively with biological targets. For instance, studies have demonstrated its utility in constructing peptidomimetics that mimic natural amino acid sequences, thereby enhancing binding affinity and therapeutic efficacy. The compound’s role in drug design has been further validated by its incorporation into several lead compounds that are currently undergoing preclinical evaluation.

Recent advancements in computational chemistry have also shed light on the mechanistic aspects of reactions involving (2R,3R)-N,N,N’,N’-Tetramethyltartramide. Molecular modeling studies have revealed insights into how this compound interacts with transition metals and organic catalysts, providing a deeper understanding of its catalytic properties. These findings have paved the way for the development of novel catalytic systems that can improve reaction efficiency and selectivity.

The pharmaceutical industry continues to explore new methodologies for incorporating (2R,3R)-N,N,N’,N’-Tetramethyltartramide into drug development pipelines. Researchers are investigating its potential use in asymmetric hydrogenation, epoxide ring opening, and other key transformations that are critical for constructing complex molecular architectures. The compound’s compatibility with various reaction conditions makes it a versatile tool for medicinal chemists seeking to optimize synthetic routes.

Moreover, the environmental impact of using (2R,3R)-N,N,N’,N’-Tetramethyltartramide as a chiral auxiliary has been a topic of interest. Efforts have been made to develop greener synthetic protocols that minimize waste generation and reduce reliance on hazardous reagents. These initiatives align with broader trends in sustainable chemistry and highlight the compound’s adaptability to evolving regulatory requirements.

In conclusion, (2R,3R)-N,N,N’,N’-Tetramethyltartramide (CAS No. 26549-65-5) is a multifaceted compound with significant implications in pharmaceutical chemistry. Its unique structural features and broad applicability make it an indispensable tool for researchers developing new drugs. As advancements continue to emerge from both experimental and computational studies, this compound is poised to play an even greater role in shaping the future of medicinal chemistry.

• 13096-65-6(D-Gluconamide,N,N-dimethyl-)
• 142082-54-0(2,5-Pyrrolidinedione, 1-butyl-3,4-dihydroxy-)
• 919480-30-1(Butanamide, 2,3-dihydroxy-4-oxo-N,N-dipropyl-, (2R,3S)-)
• 256413-09-9(1,4-Butanedione,2,3-dihydroxy-1,4-di-1-pyrrolidinyl-)
• 63126-52-3(N,N,N',N'-Tetramethyl-D-tartaramide)
• 845752-64-9(2,5-PYRROLIDINEDIONE, 1-BUTYL-3,4-DIHYDROXY-, (3R,4R)-)
• 364752-95-4(2-Pyrrolidinone,3,4-dihydroxy-1-methyl-, (3R,4S)-)
• 146330-79-2(2,3-Dihydroxy-N1,N1,N4,N4-tetramethylsuccinamide)
• 137618-50-9(Propanamide, 2,3-dihydroxy-n,n-dimethyl- (9ci))
• 249615-78-9(Butanediamide, N,N'-bis[3-(dimethylamino)propyl]-2,3-dihydroxy-,(2R,3R)-)